AG311
AG311 is an anticancer and antimetastatic agent. AG311 induces rapid necrosis in numerous cancer cell lines.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1126602-42-3
- Fòrmula: C17H15N5S
- Peso molecular:321.40
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-431 | IC50 |
10.41 μM
Compound: 2
|
Inhibition of EGFR in human A431 cells by phosphotyrosine cell-based ELISA
Inhibition of EGFR in human A431 cells by phosphotyrosine cell-based ELISA
|
[PMID: 20092323] |
| A-431 | IC50 |
14.1 μM
Compound: 2
|
Cytotoxicity against human A431 cells
Cytotoxicity against human A431 cells
|
[PMID: 20092323] |
| A498 | IC50 |
160.1 μM
Compound: 2
|
Inhibition of VEGFR1 in human A498 cells by phosphotyrosine cell-based ELISA
Inhibition of VEGFR1 in human A498 cells by phosphotyrosine cell-based ELISA
|
[PMID: 20092323] |
| HeLa | EC50 |
12.2 μM
Compound: 2
|
Activity at PI3K in human HeLa cells by ELISA
Activity at PI3K in human HeLa cells by ELISA
|
[PMID: 20092323] |
| MDA-MB-231 | IC50 |
6.9 μM
Compound: 42; AG311
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay
|
[PMID: 36893622] |
| MDA-MB-435 | IC50 |
11.9 μM
Compound: 42; AG311
|
Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay
Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo assay
|
[PMID: 36893622] |
| SF-539 | IC50 |
40.3 μM
Compound: 2
|
Inhibition of PDGFRbeta in human SF539 cells by phosphotyrosine cell-based ELISA
Inhibition of PDGFRbeta in human SF539 cells by phosphotyrosine cell-based ELISA
|
[PMID: 20092323] |
| U-251 | IC50 |
56.3 μM
Compound: 2
|
Inhibition of VEGFR2 in human U251 cells by phosphotyrosine cell-based ELISA
Inhibition of VEGFR2 in human U251 cells by phosphotyrosine cell-based ELISA
|
[PMID: 20092323] |
AG311 (0-30 μM; 48 h) shows cytotoxicity against cancer cells[1].
AG311 (10-40 μM; 0-150 min) selectively induces membrane permeabilization in breast cancer cells (compared to HUVECs)[1].
AG311 (25 μM; 20 min) induces necrosis and lacks molecular markers of apoptosis in MDA-MB-435 cells[1].
AG311 (15-25 μM) affects calcium homeostasis and induces plasma membrane depolarization in MDA-MB-435 cells[1].
AG311 (5-20 μM) induces rapid mitochondrial membrane changes and mitochondrial dysfunction in MDA-MB-435 cells[1].
AG311 (0-14 μM; 30 h) inhibits breast cancer cell migration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-435, MDA-MB-468, MDA-MB-231, MCF7, PANC-1, A375, U251, SH-SY5Y, A431, B16F10, COLO-205, DU145, HUVEC and HDF
-
Concentration:
-
Incubation Time:48 h
-
Result:The IC50 value for MDA-MB-435 (BLBC) was 13.9 μM. In other breast cancer cell lines, had similar (MDA-MB-468 and MCF7) or lower (MDA-MB-231) IC50 values compared with MDAMB-435. was least potent on noncancerous human dermal fibroblasts HDF (IC50 29.3 μM), suggesting a level of selectivity.
-
Cell Line:4T1-luc2-GFP TNBC cells
-
Concentration:0, 8, 10, 12, 14 μM
-
Incubation Time:30 h
-
Result:Significantly inhibited cell migration at multiple subtoxic doses in 4T1-luc2-GFP cells.
AG311 (45 mg/kg; i.p.; twice weekly for 30 days) inhibits tumor growth and lung metastases in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/cJ mice, 4T1 Triple Negative Orthotopic Allograft[1]
-
Dosage:23 mM, 1/15 of tumor volume
-
Administration:Intratumoral injection, once daily for 2 days
-
Result:Injected tumors had a significantly higher percentage of necrosis compared with their control-treated counterparts.
-
Animal Model:7-week-old female NCr nu/nu athymic mice, MDA-MB-435 Orthotopic Xenograft[1]
-
Dosage:45 mg/kg
-
Administration:Intraperitoneal injection, twice weekly for 30 days
-
Result:Significantly reduced primary tumor growth. Animals had fewer lung metastases at the end of the experiment compared with control-treated animals.
Chemical Information
-
No. CAS 1126602-42-3
-
Peso molecular 321.40
-
Fòrmula C17H15N5S
-
SMILES
NC1=NC(N)=C2C(NC3=C2C(SC4=CC=C(C=C4)C)=CC=C3)=N1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
AG311 Related Classifications
HY-116107 Related Classifications
Powered by Bioz